About
NovaResp is a health technology company developing cMAP®, an AI-powered platform software engineered to transform CPAP (Continuous Positive Airway Pressure) therapy for the estimated 1 billion people worldwide affected by Obstructive Sleep Apnea (OSA). cMAP® uses artificial intelligence and machine learning to analyze real-time therapy data, predict the onset of apnea episodes before they occur, and proactively adjust air pressure delivery — all during active PAP therapy sessions. By anticipating and preventing apnea events rather than merely reacting to them, cMAP® enables personalized therapy to be delivered at lower, more comfortable pressure levels. This directly addresses the #1 challenge in CPAP care: adherence. With adherence rates dropping below 50% after just three months of use, improving comfort is the critical lever for long-term treatment success. cMAP® is designed to be compatible with all major PAP machine brands, making it broadly deployable without requiring proprietary hardware. The platform creates value across the entire CPAP ecosystem: patients experience a higher quality of life, manufacturers increase sales of devices and consumables, and DMEs (Durable Medical Equipment providers) reduce labor costs while improving reimbursement rates. cMAP® is currently an investigational technology under development and not yet commercially available. NovaResp is positioning itself at the cutting edge of AI-driven medical device innovation, targeting one of the largest underserved populations in chronic disease management.
Key Features
- Predictive Apnea Prevention: Uses AI and machine learning to predict the onset of apnea episodes before they occur during PAP therapy, enabling proactive rather than reactive treatment.
- Personalized Pressure Delivery: Automatically adjusts PAP machine air pressure to the lowest effective level for each patient, maximizing comfort while maintaining therapeutic efficacy.
- Universal PAP Machine Compatibility: Designed as a platform software layer compatible with all major PAP machine brands, requiring no proprietary hardware changes.
- Real-Time Therapy Adaptation: Continuously monitors and adapts therapy parameters in real time throughout the sleep session to optimize patient outcomes.
- Multi-Stakeholder Value: Delivers measurable benefits for patients, CPAP device manufacturers, and durable medical equipment providers through improved adherence metrics.
Use Cases
- Improving long-term CPAP therapy adherence for sleep apnea patients by reducing discomfort through AI-driven personalized pressure management.
- Enabling CPAP device manufacturers to differentiate their products with embedded AI software that demonstrably improves patient outcomes and drives repeat consumable sales.
- Helping durable medical equipment providers reduce follow-up labor costs and improve device reimbursement rates through higher patient compliance metrics.
- Supporting sleep clinics and healthcare providers in delivering more effective, personalized OSA treatment plans integrated with existing PAP equipment.
- Advancing clinical research into predictive AI models for sleep-disordered breathing and real-time adaptive medical device therapy.
Pros
- Addresses Root Cause of CPAP Non-Adherence: Tackles discomfort — the primary reason patients abandon CPAP therapy — directly at the source by lowering treatment pressures through predictive AI.
- Broad Hardware Compatibility: Works with all major PAP machine brands as a software layer, making adoption scalable without costly hardware replacement.
- Multi-Stakeholder Commercial Model: Creates value simultaneously for patients, manufacturers, and DMEs, enabling diverse go-to-market and partnership opportunities.
Cons
- Not Yet Commercially Available: cMAP® is still an investigational technology under development, meaning healthcare providers and patients cannot yet access or deploy it.
- Narrow Domain Focus: The platform is exclusively targeted at PAP therapy for sleep apnea, limiting applicability outside this specific clinical use case.
Frequently Asked Questions
What is cMAP® and how does it work?
cMAP® is a platform software developed by NovaResp that uses artificial intelligence and machine learning to predict and prevent sleep apnea episodes before they occur during PAP therapy. It continuously analyzes therapy data and proactively adjusts air pressure to keep patients comfortable and compliant.
Is cMAP® currently available for use?
No. cMAP® is currently an investigational technology still under development and is not yet commercially available. NovaResp is working toward regulatory clearance and commercial launch.
Which PAP machines is cMAP® compatible with?
cMAP® has been designed for compatibility with all major PAP machine brands. It operates as a software platform layer, meaning it does not require proprietary or custom hardware.
How does cMAP® help improve CPAP adherence?
By predicting and preventing apnea episodes before they occur, cMAP® enables therapy to be delivered at lower, more comfortable pressure levels. This directly reduces discomfort — the leading cause of CPAP abandonment — helping patients stay on therapy longer.
Who benefits from NovaResp's cMAP® technology?
cMAP® creates value for three groups: patients gain improved comfort and quality of life; CPAP device manufacturers benefit from increased device and consumable sales driven by better adherence; and DMEs (Durable Medical Equipment providers) reduce labor costs and improve reimbursement rates.
